Therinject LLC is normally engaged in the advancement of cancer remedies utilizing immunology based techniques. Initially, Therinject and BMSN plan to concentrate on the veterinary market, looking to treat pets with tumors while gathering data to get human scientific trials. We anticipate this immuno-therapeutic tumor vaccine could possess an efficacy price of as high as 60 percent where 15 percent to 20 percent may be the current cure price. We believe that through the first season this immuno-therapeutic vaccine can be available we will treat roughly 2,000 animals leading to $3,000 income per animal or $6 million in first season income from veterinary medical applications.The comparison with the 2009 2009 period was negatively influenced by the dilutive effect of the FAB acquisition. Cash and Money Equivalents Anika’s cash and money equivalents at June 30, 2010 were $23.6 million, weighed against $24.on December 31 4 million, 2009. Litigation and Additional Legal Matters On July 7, 2010, Genzyme Corporation filed a complaint against the business in the United States District Court for the District of Massachusetts seeking unspecified damages and equitable comfort. The complaint alleges that the ongoing company has infringed U.S. Patent No. 5,143,724 by making MONOVISC in the United States for sale beyond your United States and can infringe U.S. Patent Nos. The Company believes that neither MONOVISC, nor its manufacture, will or will infringe any valid and enforceable state of the asserted patents.